628 Randomized Trial Comparing Systemic and Local Reactions to Controlled-Release Interferon Alpha2b and Pegylated-Interferon Alpha2b in Hepatitis C Patients Who Failed Prior Treatment

Läwitz, E.; Younossi, Zobair M.; Shiffman, M.; Gordon, S.; Ghalib, Reem; Long, W.A.; Muir, A.; McHutchison, J.

doi:10.1016/s0168-8278(09)60630-9

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a short term study controlled release interferon alfa-2b showed less flu like symptoms than peginterferon alfa-2b injected every week indicating that the controlled-release formulation may have a better tolerability. Larger trials powered to examine adverse event profiles and antiviral activity are being initiated 8. Peginterferon-λ is a pegylated type III interferon that binds to a unique receptor with more limited distribution than the type I IFN receptor.…”

Section: Future Therapies For Hcvmentioning

confidence: 99%

“…Larger trials powered to examine adverse event profiles and antiviral activity are being initiated. 8 Peginterferon-λ is a pegylated type III interferon that binds to a unique receptor with more limited distribution than the type I IFN receptor. In a phase 1 healthy volunteer study, peginterferon-λ was pharmacologically active without flu-like symptoms or hematologic side-effects.…”

Section: Future Therapies For Hcvmentioning

confidence: 99%

See 1 more Smart Citation

New treatments for chronic hepatitis C

Jang

Chung

2010

Korean J Hepatol

View full text Add to dashboard Cite

Treatments for chronic hepatitis C has evolved significantly in the past 15 years. The standard of care (SOC) is peginterferon alfa-2a/-2b with ribavirin for 48 weeks or 24 weeks in patients infected with HCV genotype 1 or 2/3, respectively. The treatment duration can be individualized based on the baseline viral load and the speed of the virologic response during treatment. However, current therapies are associated with side effects, complications, and poor patient tolerability. Therefore, there is an urgent need to identify better strategies for treating this disease. An improved sustained virologic response (SVR) can be achieved with new HCV-specific inhibitors against NS3/4A and NS5B polymerases. Recent trials have found SVR rates in patients with HCV genotype 1 infection of 61~68% and 67~75% for combining the SOC with the protease inhibitors telaprevir and boceprevir, respectively. Several new HCV-specific inhibitors such as protease inhibitors and nucleoside and non-nucleoside polymerase inhibitors as well as non-HCV-specific compounds with anti-HCV activity are currently in clinical evaluation. In this review we discuss these new treatments for chronic hepatitis C.

show abstract

Section: Future Therapies For Hcvmentioning

confidence: 99%

Section: Future Therapies For Hcvmentioning

confidence: 99%

New treatments for chronic hepatitis C

Jang

Chung

2010

Korean J Hepatol

View full text Add to dashboard Cite

show abstract

Controlled-release interferon alpha 2b, a new member of the interferon family for the treatment of chronic hepatitis C

Jansen

Bruijne

2011

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

CR2b is a slow-release microsphere preparation for the administration of plant-derived recombinant human interferon alpha 2b. Compared with Peg-interferon, treatment with CR2b shows less flu-like reactions and less depression, and is at least as effective as conventional Peg-interferon-based therapy in patients with chronic hepatitis C. CR2b has the added advantage of biweekly instead of once weekly administration. CR2b appears to cause more neutropenia than Peg-interferon alpha 2b. This may be due to higher trough serum levels of CR2b at the end of a dosing interval. The bone marrow effects of CR2b closely resemble those published for the registered Peg-interferon alpha 2a. CR2b appears to have at least comparable efficacy with fewer side effects than current registered Peg-interferons.

show abstract

Albinterferon-alfa 2b: a new treatment option for hepatitis C

Flisiak

2010

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

show abstract

628 Randomized Trial Comparing Systemic and Local Reactions to Controlled-Release Interferon Alpha2b and Pegylated-Interferon Alpha2b in Hepatitis C Patients Who Failed Prior Treatment

Cited by 3 publications

References 0 publications

New treatments for chronic hepatitis C

New treatments for chronic hepatitis C

Controlled-release interferon alpha 2b, a new member of the interferon family for the treatment of chronic hepatitis C

Albinterferon-alfa 2b: a new treatment option for hepatitis C

Contact Info

Product

Resources

About